Torrent Pharma News

With a clear indication that no additional or special tariff will be imposed by the US on generic drugs, there is a sense of relief among Indian drug companies. The US healthcare system, too, must be relieved, given that India is the biggest supplier of generic drugs to the American market. Any increase in the cost of these medicines would have led to a disruption in the US healthcare system. Now that the tariff threat – which has been troubling Indian companies for the past year – is seemingly a thing of the past, will things get better on the street for Indian pharma companies?

The market hates uncertainty. Post the big reforms (GST and banking), the markets should have ideally been in upbeat mode this festive season. But the US tariffs are a downer. And while the street is clearly hoping that an India-US trade pact will be inked soon, no deal is done till it is actually done. And given that the tariffs impact many sectors, the bears are lurking around just in case Trump puts a spanner in the works and everything goes south. As an investor, there is no point trying to guess what will happen. Focus, instead, on good businesses with an assured market and sound management. That will pay off in the long term.

Credit Rating

Credit Rating

Markets closed higher on Friday, with Nifty testing key resistance at 24,900. Analysts predict further recovery if this level is breached. Several companies are in focus today. HDFC Bank reported loan growth. DMart and Bajaj Housing Finance showed strong revenue and disbursement gains. Vedanta pushed its demerger deadline. Tata Steel received a demand letter. Bajaj Finance saw AUM jump.

Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015

Newspaper advertisement in respect of special window for re-lodgement of transfer request of physical shares

Disclosure u/r 30 of SEBI(LODR) Regulations, 2015

Intimation of the Closure of Trading Window

Redemption of commercial papers issued under ISIN INE685A14153

Intimation regarding issue of Commercial paper

Disclosure under Regulation 30 and other applicable provisions of SEBI LODR Regulations, 2015

Redemption of Commercial papers issued under ISIN: INE685A14146

Intimation regarding issue of Commercial papers

Acquisition

Newspaper Advertisement - 100 days IEPFA campaign

There are two ways to look at the hope which the street is reflecting when it comes to a possible India-US tariff deal. One, it will bring down the tariffs (raised recently) on a number of products. Two, it removes the fear hanging over some companies and sectors that they may be put on the tariff list if the situation is not resolved. Now, which is the sector where the fear of a possible tariff hike is most palpable? The answer is pharma. The reason it has not been tariffed by President Trump is that any additional duty will mean higher medicine costs in the US. And it will lead to higher inflation. But then you don't know what he might do. So, there is an element of “what if” at the moment, and getting that removed is good enough.

Newspaper advertisement in respect of special window for re-lodgement of transfer requests of physical shares

Announcement under reg 30

Transcript of conference call

Declaration of Voting result and scrutinizer report

Audio Recording of Conference call with Analysts / Investors on Financial Results for the quarter ended 30th June, 2025

Torrent Pharmaceuticals announced a 20% year-on-year increase in consolidated net profit, reaching Rs 548 crore for the June quarter. This growth was fueled by robust sales across key markets, including India and the US. India revenues surged by 11% to Rs 1,811 crore, while US business revenues rose by 19% to Rs 308 crore. Shares of Torrent Pharma closed 0.

Appointment of Managing Director of the Company

Change in Senior Management Personnel

Appointment of Secretarial Auditors

Proceedings of 52nd AGM held on 28-jul-25

Presentation to analysts on unaudited Consolidated Financial Results for the quarter ended 30-Jun-25

Outcome of Board Meeting dated 28-Jul-25

Results for quarter ended 30-Jun-25

Indian markets closed negatively for the second straight day, with the BSE Sensex dropping over 700 points and the Nifty50 falling below 24900. Healthcare saw buying interest, while oil & gas, power, utilities, and capital goods experienced selling pressure. Analysts suggest holding Torrent Pharma, considering buying SBI Life on dips, and avoiding eClerx due to potential reversal signals.

Torrent Pharma signals a potential uptrend. The stock recently emerged from a nine-month consolidation. Experts suggest a buying opportunity for short-term traders. The target price is above Rs 3,900 within 1-2 months. The stock surpassed a key resistance level. Technical indicators support a bullish outlook. Religare Broking recommends accumulating positions.

Technical analysis identifies select stocks that may gain momentum even in volatile markets. Here are the technical calls for today.

The Nifty Pharma index was trading 0.95 per cent down at 22317.3.

Post Quarterly Financial Result Conference call with investors / analyst We hereby inform that the Company has scheduled a teleconference with Investors / Analyst on 28th July, 2025 at 06:30 P.M. to discuss the financial performance of the Company for the quarter ended 30th June, 2025.

Torrent Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/07/2025 ,inter alia, to consider and approve the Audited Financial Results on Standalone basis and Unaudited Financial Results with limited review on Consolidated basis of the Company for the quarter ended on 30-Jun-25. In the above meeting, the Board would also consider the Issue of Unsecured or Secured Redeemable Non Convertible Debentures or Bonds by way of private placement.

The Nifty Pharma index was trading 0.59 per cent down at 22545.95.

The Nifty Pharma index closed 0.38 per cent up at 22680.35.

The Nifty Pharma index was trading 0.27 per cent up at 22655.9.

Torrent Pharma shares, currently at Rs 3,404.90, have broken out from a falling trendline, signaling a potential bullish trend. Supported by increased trading volumes and positive RSI, the stock may rally towards Rs 3,600-Rs 3,700 if it sustains above Rs 3,475. Choice Broking suggests a Bull Call Ladder strategy to capitalize on the expected upward momentum.